Immunosuppressive activities of adenosine in cancer
Top Cited Papers
- 1 August 2016
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 29, 7-16
- https://doi.org/10.1016/j.coph.2016.04.001
Abstract
No abstract availableKeywords
Funding Information
- NHMRC
- Cancer Council of Victoria
This publication has 100 references indexed in Scilit:
- CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer GrowthJournal of Biomedicine and Biotechnology, 2012
- NT5E CpG island methylation is a favourable breast cancer biomarkerBritish Journal of Cancer, 2012
- NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificityBritish Journal of Cancer, 2012
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptorCancer Immunology, Immunotherapy, 2011
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences of the United States of America, 2010
- Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck CancerClinical Cancer Research, 2009
- Adenosine A 2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Suppression of inflammatory and immune responses by the A2Aadenosine receptor: an introductionBritish Journal of Pharmacology, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionThe Journal of Experimental Medicine, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006